Impact of ontogeny on linezolid disposition in neonates and infants

Clinical Pharmacology and Therapeutics

Volumn 74, Issue 5, 2003, Pages 413-422

  Kearns, Gregory L ^a   Jungbluth, Gail L ^b   Abdel Rahman, Susan M ^b   Hopkins, Nancy K ^b   Welshman, Ian R ^b   Grzebyk, Rosie P ^b   Bruss, Jon B ^b   Van Den Anker, John N ^b  

^a CHILDREN S MERCY HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

LINEZOLID;

AGE; ANALYTIC METHOD; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DOSE REGIMEN; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INFUSION; DRUG TOLERABILITY; EVALUATION; FEMALE; GESTATIONAL AGE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INFANT; MALE; MASS SPECTROMETRY; MULTICENTER STUDY; NEWBORN; ONTOGENY; OPEN STUDY; PARAMETER; PHARMACOKINETICS; PLASMA CLEARANCE; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SINGLE DRUG DOSE; TECHNIQUE;

ACETAMIDES; AGING; ANTI-INFECTIVE AGENTS; AREA UNDER CURVE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; GESTATIONAL AGE; HUMANS; INFANT; INFANT, NEWBORN; INFANT, PREMATURE; MALE; OXAZOLIDINONES;

EID: 0242319822     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(03)00226-1     Document Type: Article

References (19)

1. Dresser LD, Rybak MJ. The pharmacologic and bacteriologic properties of oxazolidinones, a new class of synthetic antimicrobials. Pharmacotherapy 1998;18:456-62.
2. Shinabarger DL, Marotti KR, Murray RW, Lin AH, Melchior EP, Swaney SM, et al. Mechanism of action of oxazolidinones: effect of linezolid and eperezolid on translation reactions. Antimicrob Agents Chemother 1997;41:2132-6.
3. Swaney SM, Aoki H, Ganoza CM, Shinabarger DL. The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria. Antimicrob Agents Chemother 1998; 42:3251-5.
4. Kaplan SL, Patterson L, Edwards KM, Azimi PH, Bradley JS, Blumer JL, et al. Linezolid for the treatment of community-acquired pneumonia in hospitalized children. Pediatr Infect Dis J 2001;20:488-94.
5. Kearns GL, Abdel-Rahman SM, Blumer JL, Reed MD, James LP, Jacobs RF, et al. Single dose pharmacokinetics of linezolid in infants and children. Pediatr Infect Dis J 2000;19:1178-84.
6. Hopkins NK, Stalker DJ, Johnson RA, Gammill JC, Cazers AR. Determination of linezolid, PNU-100766, in human plasma by isocratic HPLC/MS/MS. In: Proceedings of the Tenth International Symposium on Pharmaceutical and Biomedical Analysis; May 9-12, 1999; Washington, DC. Washington: The Symposium; 1999.
7. Kearns GL. Impact of developmental pharmacology on pediatric study design: overcoming the challenges. J Allergy Clin Immunol 2000;106(Suppl):S128- 38.
8. Andes D, Van Outgrip ML, Craig WA. Pharmacodynamic activity of a new oxazolidinone, linezolid, in an animal infection model [abstract]. In: Thirty-eighth Interscience Conference on Antimicrobial Agents and Chemotherapy; September 15-18, 1998; San Diego, California. San Diego: The Conference; 1998.
9. Parvez FM, Jarvis WR. Nosocomial infections in the nursery. Semin Pediatr Infect Dis 1999;10:119-29.
10. Centers for Disease Control and Prevention. Drug-resistant Streptococcus pneumoniae - Kentucky and Tennessee, 1993. MMWR Morb Mortal Wkly Rep 1994;43:23-5.
11. Arditi M, Mason EO Jr, Bradley JS, Tan TQ, Barson WJ, Schutze GE, et al. Three-year multicenter surveillance of pneumococcal meningitis in children: clinical characteristics and outcomes related to penicillin susceptibility and dexamethasone use. Pediatrics 1998;102:1087-97.
12. Malik RK, Montecalvo MA, Reale MR, Reale MR, Li K, Maw M, et al. Epidemiology and control of vancomycin-resistant enterococci in a regional neonatal intensive care unit. Pediatr Infect Dis J 1999;18:352-6.
13. Singh-Naz N, Sleemi A, Pilis A, Patel KM, Campos JM. Vancomycin resistant Enterococcus faecium colonization in children. J Clin Microbiol 1999;37:413-6.
14. Henning KJ, Delencastre H, Eagan J, Boone N, Brown A, Chung M, et al. Vancomycin-resistant Enterococcus faecium on a pediatric oncology ward: duration of stool shedding and incidence of clinical infection. Pediatr Infect Dis J 1996;15:848-54.
15. Slatter JG, Stalker DJ, Feenstra KL, Welshman IR, Bruss JB, Sams JP, et al. Pharmacokinetics, metabolism and excretion of linezolid following an oral dose of [(14)C]linezolid to healthy human subjects. Drug Metab Dispos 2001;29:1136-45.
16. Bouza E, Munoz P. Linezolid: pharmacokinetic characteristics and clinical studies. Clin Microbiol Infect 2001; 7(Suppl 4):75-82.
17. Welshman IR, Sisson TA, Jungbluth GL, Stalker DJ, Hopkins NK. Linezolid absolute bioavailability and the effect of food on oral bioavailability. Biopharm Drug Dispos 2001;22:91-7.
18. Gee T, Ellis R, Marshall G, Andrews J, Ashby J, Wise R. Pharmacokinetics and tissue penetration of linezolid following multiple oral doses. Antimicrob Agents Chemother 2001;45:1843-6.
19. Sisson TL, Jungbluth GL, Hopkins NK. Age and sex effects on the pharmacokinetics of linezolid. Eur J Clin Pharmacol 2002;57:793-7.